Rituximab

Questions discussed in this category

What is your approach to maintenance treatment in a patient with Sjogren's who received rituximab for mononeuritis multiplex?

And how would you monitor response?

1 Answer available

What is your approach to dosing and duration of rituximab for refractory lupus nephritis not responsive to cyclophosphamide or mycophenolate?

Do you add low-dose mycophenolate to use in combination with Rituximab in these patients?

1 Answer available

Do you choose rituximab or calcineurin inhibitors for patients with class IV/V lupus nephritis who are refractory to standard of care therapies?

1 Answer available

Do you utilize post-vaccination IgG titers to detect common variable immunodeficiency in patients who are about to start or are actively on B cell depleting therapy?

2 Answers available

For patients with scleroderma at high risk of renal crisis, would you feel comfortable giving corticosteroids as pre-medication for rituximab?

1 Answer available

How do you approach management of a patient with persistent EBV infection and MAS despite treatment with Rituximab, anakinra and canakinumab?

Would you consider alternative B cell depleting therapies such as ofatumumab or ocrelizumab?

1 Answer available

Do you prefer to taper rituximab by extending the interval between doses or decreasing the actual dose administered for RA patients who have achieved longstanding remission?

3 Answers available

Do you hold rituximab for cataract surgery?

If so, when do you recommend timing for the cataract surgery?

3 Answers available

How would you approach treating a patient with active rheumatoid arthritis and a history of treated lymphoma that is currently in remission?

Given the controversy in the literature regarding TNFi or MTX associated lymphoma in patients with RA.

1 Answer available

Is there a role for antibody testing to confirm vaccine response for patients on rituximab after COVID-19 vaccination?

1 Answer available

How will you use REGEN-COV (casirivimab/imdevimab-monoclonal antibody treatment recently approved under EUA as post-exposure prophylaxis for Covid) in rheumatic patients on immunosuppressive therapy?

Would you consider this for patients on B-cell depleting therapies or more broadly for other immunosuppressive agents?

2 Answers available

Are there particular concerns related to the use of B-cell depletion therapies such as rituximab for rheumatic disease during the COVID-19 pandemic?

1 Answer available

Are there AAV patients for whom you would consider combination therapy with cyclophosphamide and rituximab?

1 Answer available

What is considered an adequate treatment period to assess response of AAV induction therapy with rituximab or cyclophosphamide?

1 Answer available

How do you handle hypogammaglobulinemia detected in patients prior to maintenance rituximab infusion?

2 Answers available

Which ANCA vasculitis patients are better candidates for cyclophosphamide rather than rituximab?

2 Answers available

What agents can you use for treatment induction besides rituximab in cryoglobulinemic vasculitis (without hepatitis)?

1 Answer available

Do you recommend on-demand versus fixed-schedule dosing for rituximab maintenance in ANCA vasculitis?

If you use both, how do you decide which to use for a particular patient?

2 Answers available

In the treatment of lupus nephritis, which patients may benefit from the use of rituximab or other B-cell depleting agents during induction?

1 Answer available

Papers discussed in this category

The New England journal of medicine, 2010-07-15

Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis.

Medicine (Baltimore),

The Five-Factor Score revisited: assessment of prognoses of systemic necrotizing vasculitides based on the French Vasculitis Study Group (FVSG) cohort.

The New England journal of medicine, 2010-07-15

Rituximab versus cyclophosphamide for ANCA-associated vasculitis.

Arthritis and rheumatism, 2012-04

Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study.

Ann Rheum Dis, 2013 Jun 05

Prospective observational single-centre cohort study to evaluate the effectiveness of treating lupus nephritis with rituximab and mycophenolate mofetil but no oral steroids.

Ann. Rheum. Dis., 2018 Apr 25

Comparison of individually tailored versus fixed-schedule rituximab regimen to maintain ANCA-associated vasculitis remission: results of a multicentre, randomised controlled, phase III trial (MAINRITSAN2).

Ann. Rheum. Dis., 2017 May 25

Randomised controlled trial of prolonged treatment in the remission phase of ANCA-associated vasculitis.

Ann. Rheum. Dis., 2018 May 03

Long-term efficacy of remission-maintenance regimens for ANCA-associated vasculitides.

Annals of the rheumatic diseases, 2009-03

EULAR recommendations for the management of primary small and medium vessel vasculitis.

JAMA network open, 2018-11-02

Association of Immunoglobulin Levels, Infectious Risk, and Mortality With Rituximab and Hypogammaglobulinemia.

Rheumatol Int, 2020 Sep 18

High rates of severe disease and death due to SARS-CoV-2 infection in rheumatic disease patients treated with rituximab: a descriptive study.

Kidney international reports, 2018-03

Combination Therapy With Rituximab and Cyclophosphamide for Remission Induction in ANCA Vasculitis.

N Engl J Med, 2020 Feb 13

Plasma Exchange and Glucocorticoids in Severe ANCA-Associated Vasculitis.

Rheumatology (Oxford),

A novel glucocorticoid-free maintenance regimen for anti-neutrophil cytoplasm antibody-associated vasculitis.

N Engl J Med, 2021 Aug 04

Subcutaneous REGEN-COV Antibody Combination to Prevent Covid-19.

Ophthalmology and therapy, 2023 Aug 21

Cataract Surgery Outcomes in Patients with Non-ocular Autoimmune Disease.

Annals of the rheumatic diseases, 2011 Sep 16

Efficacy of rituximab in primary Sjogren's syndrome with peripheral nervous system involvement: results from the AIR registry.

Rheumatology (Oxford, England), 2011-12

Retreatment with rituximab based on a treatment-to-target approach provides better disease control than treatment as needed in patients with rheumatoid arthritis: a retrospective pooled analysis.

Annals of the rheumatic diseases, 2021 Oct 06

B-cell depletion with obinutuzumab for the treatment of proliferative lupus nephritis: a randomised, double-blind, placebo-controlled trial.

Lupus, 2020 Oct 20

What is the value of repeat kidney biopsies in patients with lupus nephritis?

Cureus, 2023 May 10

Treatment Using Both Voclosporin and Belimumab in Four Patients With Lupus Nephritis.

Clinical journal of the American Society of Nephrology : CJASN, 2009 Mar 04

Rituximab in severe lupus nephritis: early B-cell depletion affects long-term renal outcome.

Rituximab

Questions discussed in this category

Papers discussed in this category

Related Topics